Private Harbour Investment Management & Counsel LLC acquired a new position in shares of Heron Therapeutics Inc (NASDAQ:HRTX) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 19,905 shares of the biotechnology company’s stock, valued at approximately $486,000.
A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Bank of New York Mellon Corp increased its stake in Heron Therapeutics by 4.7% in the third quarter. Bank of New York Mellon Corp now owns 313,312 shares of the biotechnology company’s stock worth $9,916,000 after purchasing an additional 13,928 shares during the period. JPMorgan Chase & Co. increased its stake in shares of Heron Therapeutics by 458.0% in the third quarter. JPMorgan Chase & Co. now owns 206,802 shares of the biotechnology company’s stock worth $6,545,000 after acquiring an additional 169,738 shares during the last quarter. Legal & General Group Plc increased its stake in shares of Heron Therapeutics by 151.7% in the third quarter. Legal & General Group Plc now owns 25,885 shares of the biotechnology company’s stock worth $819,000 after acquiring an additional 15,599 shares during the last quarter. Vanguard Group Inc. increased its stake in shares of Heron Therapeutics by 36.7% in the third quarter. Vanguard Group Inc. now owns 6,193,249 shares of the biotechnology company’s stock worth $196,016,000 after acquiring an additional 1,661,318 shares during the last quarter. Finally, Boston Advisors LLC increased its stake in shares of Heron Therapeutics by 11.7% in the fourth quarter. Boston Advisors LLC now owns 24,740 shares of the biotechnology company’s stock worth $642,000 after acquiring an additional 2,595 shares during the last quarter.
HRTX stock opened at $18.19 on Friday. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.40 and a quick ratio of 4.06. Heron Therapeutics Inc has a 52-week low of $16.20 and a 52-week high of $42.90. The stock has a market cap of $1.45 billion, a price-to-earnings ratio of -7.45 and a beta of 1.45.
Heron Therapeutics (NASDAQ:HRTX) last released its quarterly earnings results on Thursday, May 9th. The biotechnology company reported ($0.80) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.50) by ($0.30). Heron Therapeutics had a negative net margin of 194.43% and a negative return on equity of 49.22%. The firm had revenue of $31.60 million for the quarter, compared to the consensus estimate of $28.04 million. During the same quarter last year, the company earned ($1.09) earnings per share. The firm’s revenue was up 172.4% on a year-over-year basis. As a group, equities analysts anticipate that Heron Therapeutics Inc will post -2.47 EPS for the current fiscal year.
In other news, Director Waage Christian purchased 1,400 shares of the firm’s stock in a transaction on Wednesday, May 15th. The stock was bought at an average cost of $18.04 per share, for a total transaction of $25,256.00. Following the completion of the acquisition, the director now directly owns 1,400 shares of the company’s stock, valued at $25,256. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 12.56% of the stock is owned by corporate insiders.
A number of equities analysts have recently weighed in on the stock. BidaskClub raised shares of Heron Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, February 20th. Cantor Fitzgerald downgraded shares of Heron Therapeutics from an “overweight” rating to a “neutral” rating in a research note on Monday, March 4th. ValuEngine downgraded shares of Heron Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, March 1st. Stifel Nicolaus reaffirmed a “buy” rating and issued a $54.00 price target on shares of Heron Therapeutics in a research note on Friday, February 22nd. Finally, Northland Securities set a $55.00 price target on shares of Heron Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, April 2nd. Three research analysts have rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $51.20.
ILLEGAL ACTIVITY NOTICE: “19,905 Shares in Heron Therapeutics Inc (HRTX) Purchased by Private Harbour Investment Management & Counsel LLC” was first published by Modern Readers and is owned by of Modern Readers. If you are reading this report on another website, it was illegally copied and reposted in violation of United States and international trademark & copyright laws. The legal version of this report can be read at https://www.modernreaders.com/news/2019/05/17/19905-shares-in-heron-therapeutics-inc-hrtx-purchased-by-private-harbour-investment-management-counsel-llc.html.
Heron Therapeutics Company Profile
Heron Therapeutics, Inc, a biotechnology company, engages in developing treatments to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.
Featured Story: What is Depreciation?
Want to see what other hedge funds are holding HRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Heron Therapeutics Inc (NASDAQ:HRTX).
Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.